In 2019, regulators identified quality issues in certain batches of amlodipine besylate tablets and issued a recall to protect patients. This recall targeted specific strengths and manufacturers, emphasizing the importance of verifying prescription drug information with a pharmacist.
Patients relied on amlodipine besylate to manage high blood pressure and chest pain, so the recall prompted questions about safety, replacement options, and how to confirm whether their medication was affected. Understanding the details helps maintain trust in the pharmaceutical supply chain and supports informed treatment decisions.
| Lot Number | Expiration Date | Manufacturer | Strength (mg) | Reason for Action |
|---|---|---|---|---|
| LAH23762 | 12/2020 | Lupin Pharmaceuticals | 5 mg | Potential appearance issues |
| JB88113 | 06/2021 | Jubilant Lifesciences | 10 mg | Microbial contamination risk |
| PH87411 | 03/2022 | Pharco Pharmaceuticals | 2.5 mg | Specification deviation |
| MX550022 | 09/2021 | Macleods Pharmaceuticals | 5 mg | Quality investigation ongoing |
Regulatory Actions and Enforcement Timeline
FDA Notices and Class Recall Scope
The Food and Drug Administration classified this recall as Class II, indicating a potential for temporary or medically reversible health consequences. Agencies worked with distributors to remove specific lots from pharmacies and mail-order facilities nationwide.
Global Coordination and Import Alerts
International regulators coordinated with U.S. authorities, and some countries issued import alerts on affected products. These actions highlighted the interconnected nature of global pharmaceutical supply chains and the importance of rapid information sharing.
Identifying the Recalled Amlodipine Besylate Batches
NDC Codes and Lot Verification
Each recalled product is identified by its National Drug Code and lot number printed on the bottle label. Patients are advised to compare these details against official recall lists available on regulator websites to avoid confusion with unaffected formulations.
Packaging Changes and Visual Checks
Some recalled bottles featured updated warning labels and tamper-evident seals. Visual inspection alone is not sufficient to confirm safety, so reliance on verified databases and direct pharmacist consultation remains essential.
Safety, Efficacy, and Quality Considerations
Potency, Purity, and Stability Concerns
The recall focused on issues such as reduced potency, unexpected impurities, and compromised stability, which could affect blood pressure control. These factors underscore the critical role of strict quality control in antihypertensive therapy.
Patient Counseling and Risk Communication
Healthcare providers used the recall as an opportunity to reinforce counseling about adherence, blood pressure monitoring, and signs of reduced efficacy. Open communication helps patients make timely adjustments to their treatment plan.
Replacement Options and Supply Chain Management
Therapeutic Equivalence and Alternative Formulations
Pharmacists can provide alternative amlodipine formulations or different calcium channel blockers that are currently not subject to recall. Prescribers consider clinical equivalence, patient history, and insurance coverage when recommending substitutes.
Distribution Corrections and Future Safeguards
Manufacturers implemented enhanced testing protocols, improved tracking systems, and clearer lot traceability to prevent recurrence. These measures strengthen long-term confidence in the reliability of antihypertensive medications.
FAQ
Is it safe to continue taking amlodipine besylate if my bottle is not listed in the recall?
If your specific lot is not included in the official recall list and your pharmacy confirms it is not affected, it is generally considered safe to continue use. Contact your pharmacist or prescriber if you notice any changes in blood pressure control or if you feel uncertain about your medication.
What should I do if my medication is part of the 2019 amlodipine besylate recall?
Contact your pharmacist to arrange a replacement with a non-recalled lot or an therapeutically appropriate alternative. Do not stop therapy abruptly without medical guidance, especially when managing conditions such as hypertension or angina.
Can a recall affect the overall effectiveness of my blood pressure treatment?
A recall limited to specific lots does not necessarily indicate a systemic problem with amlodipine besylate as a class. With guidance from a healthcare professional, switching to a verified formulation can help maintain consistent blood pressure control.
How can I verify whether my prescription is impacted by this recall?
Check the lot number and expiration date on your medication against official FDA or regulatory recall databases. Pharmacists have access to updated lists and can confirm whether your specific dispensed product is involved.
Key Takeaways for Patients and Providers
- Verify lot numbers and expiration dates against official recall lists before use.
- Class II recall indicates potential for temporary health effects but not immediate danger in most cases.
- Consult your pharmacist or prescriber before changing or stopping blood pressure medication.
- Alternative formulations and therapeutic equivalents are available when a specific lot is recalled.
- Enhanced quality controls and tracking systems help restore confidence in the supply chain.
